Postpartum Suicide is Tragic, But Preventable
Programs are necessary to implements strategies for reducing the risk of suicide and infanticide in postpartum women, especially in women at risk for postpartum psychosis.
Programs are necessary to implements strategies for reducing the risk of suicide and infanticide in postpartum women, especially in women at risk for postpartum psychosis.
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
For women, the postpartum period appears to be a time of increased risk for conversion to bipolar disorder in women previously diagnosed with major depressive disorder. Sharma and colleagues observed that the rate of diagnostic [...]
Depressive symptoms were assessed in a group of 622 Canadian first-time fathers during their partner’s third trimester using the Edinburgh Postnatal Depression Scale (EPDS). The prevalence of depressive symptoms in fathers was 13.76% at 2 [...]
A mother’s emotional relationship with her baby begins during her pregnancy. After her baby is born, the mother’s feelings about her baby, described as bonding, typically grow and intensify and become the foundation of the [...]
All women are at risk for depression during pregnancy and the postpartum period, and there is growing evidence to suggest that poor sleep during pregnancy and the postpartum period may be a risk factor for [...]
Publish date: September 10, 2019 By Lee S. Cohen, MD The last decade has brought increasing awareness of the need to effectively screen for postpartum depression, with a majority of states across the country now having [...]
It has been a few months since Zulresso (brexanolone), the new FDA-approved treatment for postpartum depression, has been available. At our clinic, we have had multiple queries regarding how to obtain treatment with Zulresso. One [...]
We’ve come a long way. Prior to the 1980s, most new mothers had never heard of postpartum depression. Over the last few decades we have made considerable progress in educating women about their risk for [...]
Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]